Unique ubiquity

Targeting monoubiquitinated MALT1 in diffuse large B cell lymphoma

A University of Lausanne team has turned to the U.K.'s MRC Technology for help in developing a therapeutic from the team's 2013 finding that monoubiquitination can activate the protease MALT1 in diffuse large B cell lymphoma (DLBCL). The goal of the collaboration, announced last

Read the full 440 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE